Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what information his Department holds on the number of children who have (a) been harmed by sodium valproate use during pregnancy and (b) received a diagnosis of Foetal Valproate Spectrum.

The Department does not hold information regarding the number of children that have been harmed by sodium valproate use during pregnancy, or those who have received a diagnosis of foetal valproate spectrum.

The National Disease Registration Service in NHS England collects and quality assures data about people with congenital conditions and rare conditions across the whole of England.

In the most recent official statistics on congenital conditions in England, the 2022 Congenital Condition Official Statistics Report, which contains information on congenital conditions detected in babies delivered in England between 1 January and 31 December 2022, as well as in previous publications of this series back to its inception in 2018, there were no foetus' or babies reported to have a diagnosis of fetal sodium valproate syndrome.

It is likely that while some of the individual conditions, for instance neural tube defects, cardiac, oro-facial clefts, and/or limb difference, that can be associated with this condition are recorded on the register, the overarching diagnosis of fetal sodium valproate syndrome may not yet be registered because fetal sodium valproate syndrome may take more than a year after birth to be confirmed as a diagnosis, so the number reported in any year is the minimum level in the population.

The National Disease Registration Service is assessing the feasibility and reliability of better ascertainment of fetal sodium valproate syndrome by linking the congenital condition register to primary care prescription data.